UNSPSC 51181924: Panomifene

This classification denotes an antiestrogen with the molecular formula C25H24F3NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GCW5E728OC, chemically known as ethanol, 2-((2-(4-(3,3,3-trifluoro-1,2-diphenyl-1-propenyl)phenoxy)ethyl)amino)-, (e)- but generally known as panomifene, which bears US NIH Compound Identifier 3033654. European Medicines Agency schedules Panomifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09606MIG.

UNSPSC 51181924 Panomifene, a Commodity code, encompasses pharmaceutical products sourced through state and local cooperative purchasing agreements for distribution across government healthcare facilities. State and local governments procure generic pharmaceuticals and over-the-counter products under this code via multi-state cooperative purchasing vehicles, with solicitations requiring manufacturers to supply products through authorized wholesalers and meet FDA compliance, cGMP certification, and Drug Supply Chain Security Act requirements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents a major issuing body for pharmaceutical procurement serving multiple state and local member entities across participating jurisdictions including Oregon. Vendors responding to pharmaceutical solicitations under this code must maintain substantial insurance coverage, establish contractual relationships with designated wholesalers equipped with chargeback systems, and demonstrate pricing flexibility across multiple formats including flat pricing, net price arrangements, or WAC-minus structures.

MMCAP issued a Request for Proposal on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026. The solicitation emphasizes price competitiveness (weighted at 75 percent of evaluation), with additional weight given to fixed pricing for the contract term (10 percent), EDI capability (5 percent), compliance with data format requirements (5 percent), and agreement to a 3 percent administrative fee (5 percent). Vendors must supply detailed product information including NDC codes, SKUs, UPCs, and manufacturing locations, with all products required to be available in the marketplace by May 15, 2026. The contract term is two years for new responders with optional extensions at MMCAP's discretion, while incumbent vendors' amendments align with existing expiration dates through June 30, 2028. MMCAP reserves multi-award authority based on therapeutic considerations, product availability, and member-specific needs, with performance penalties ranging from $200 to $1,500 per violation for reporting delays or onboarding failures.